6
Participants
Start Date
September 14, 2021
Primary Completion Date
October 26, 2023
Study Completion Date
October 26, 2023
Mirdametinib
Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously
Fulvestrant
"The starting dose of mirdametinib in combination with fulvestrant in each Dose Level will be as follows:~* Dose Level 1: mirdametinib 4 mg BID PO + fulvestrant~* (Only to be triggered pending DLTs on higher Dose Levels as described below)~ * Dose Level -2: mirdametinib 2 mg BID PO continuous + fulvestrant, and Dose Level -2INT: mirdametinib 2 mg BID PO on 3 weeks on, 1 week off + fulvestrant"
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
Memorial Sloan Kettering Cancer Center
OTHER